Leading innovation to enhance industrial production of gene therapy at scale
Large scale manufacturing processes of viral vectors in a cost-efficient fashion is certainly one of the key challenges that the bioproduction of gene therapy products is facing today. Improving constantly processes yields at every scale is at the core of our innovation efforts.
We are at the forefront of innovation for bioprocess improvement. As a spin off from Genethon, our fully dedicated Innovation team is working jointly with Genethon’s Innovation team. Our objective is to adapt ourselves to the challenges of evolving needs of our clients and continuously deliver on all commitments as a long term, sustainable and competitive supplier.
We are working on increasing process productivity through a broad range of innovative technologies. For instance, we have developed a high yield AAV platform using the gold standard triple transfection process, with a new transfecting agent and a high producer clone (proprietary). For lentiviral vectors, we have a patented large scale suspension process, using a new transfectant.
Genetically modified Cells (ex-vivo Gene Therapy)
Yposkesi works on the optimization of the transduction process of genetically modified cells, including CD34+ hematopoietic cells and T-cells. The activities focus on the automation of processes using robotics, development of closed systems, optimization of cell transduction, cryostorage and also the development of analytical methods for the product characterization (identity, purity and potency assay). We have a dedicated lab area for that activity, including 2 class B rooms and a QC lab.